Tempus AI, Inc.
Chicago, IL Doing business as Tempus Labs Inc.
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- Ambry Genetics Corporation · Aliso Viejo, CA E1VBXEM76NC5
-
- SAM.gov registration date
- Physical address
- 600 W Chicago Ave #510, Chicago, IL 60654, USA
- Website
- tempus.com
- Founded
- 2015
- Employees
- 1K-5K
- Estimated annual revenue
- $500M-$1B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $30,534,978 |
| FY2025 | $18,460,020 |
| FY2024 | $10,192,215 |
| FY2023 | $1,863,322 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $19,084,914 | |
| 2 | Department of Health and Human Services | $11,450,065 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Center for functional validation and evaluation of encode enhancer regions | National Human Genome Research Institute (NIH) | $2,788,491 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Fulgent Genetics, Inc. | El Monte, CA | 621511 Medical Laboratories |
| Broad Clinical Laboratories, LLC | Cambridge, MA | 621511 Medical Laboratories |
| Baylor Miraca Genetics Laboratories LLC | Houston, TX | 621511 Medical Laboratories |
| Infinity Biologix LLC D.b.a. Sampled | Piscataway, NJ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Invitae Corporation | — | 621511 Medical Laboratories |
About the company
Tempus AI, Inc., doing business as Tempus Labs Inc., is a Chicago-based precision medicine and genomic sequencing company that delivers tumor-normal matched genomic testing, DNA methylation analysis, and comprehensive genomic profiling services to the Department of Veterans Affairs and the National Institutes of Health as a prime contractor operating under full-and-open competition with no set-aside designations. The company operates as a for-profit corporate entity with a named subsidiary, Ambry Genetics Corporation, and competes exclusively as a prime contractor (100% of recent awards).
Tempus's federal capability portfolio centers on genomic testing and analysis to support precision oncology and personalized cancer treatment for veteran patients. The company holds two single-award IDIQs with the VA: a $64.3 million contract awarded January 28, 2022, running through January 27, 2027, for tumor-normal matched genomic testing services; and a $35.2 million contract awarded March 2, 2026, running through March 1, 2031, for TASSO+ assay testing supporting the VA's Million Veteran Program (MVP). Under the older VA IDIQ, Tempus has delivered six task orders ranging from $293,819 to $7.99 million, with recent orders in January 2026 ($5.53 million with VAAR Clause 852.222-71 compliance incorporation), January 2025 ($5.72 million), January 2024 ($5.99 million), and January 2023 ($7.99 million). Under the MVP TASSO+ IDIQ, Veterans Integrated Service Network 1 has issued three task orders to date: $2.7 million in March 2026, $8.39 million in July 2026, and $2.5 million in September 2026, all completing in 2027. The National Institutes of Health awarded a $59.2 million definitive contract for adaptive clinical research organization support services on September 18, 2025, with time-and-materials pricing and completion scheduled for September 17, 2030.
Customer concentration is heavily weighted to the Department of Veterans Affairs. The top five customer agencies account for 94% of awards by count and 100% by potential value, with VA Headquarters dominating at 7 awards and $91.8 million combined potential value, followed by NIH with $59.2 million (1 award) and VA Veterans Integrated Service Network 1 with 4 awards and $48.8 million. VA Veterans Integrated Service Network 7 and NCI account for the remaining activity at $67 thousand and $135 thousand respectively. The gap between award count and dollar concentration reflects the presence of two large VA IDIQs anchoring most of the potential value while the NIH definitive contract, though single-award, carries substantial ceiling value.
Activity has accelerated sharply. Tempus received 3 awards in 2022, declined to 1 in 2023, then 2 each in 2024 and 2025, before jumping to 5 awards in 2026. Six awards with ultimate completion dates in the next twenty-four months carry combined potential value of $30.8 million, representing significant recompete exposure on the VA tumor-normal matched testing deliveries and the MVP TASSO+ orders due to expire in 2027. The company has obligated $68.2 million (34% of combined potential value) across all awards as of the snapshot date, indicating execution is underway on multiple concurrent delivery orders.
Service Contract Inventory reports reflect nascent SCI-reportable activity: $5.3 million in invoiced federal services revenue in FY2025 across 13.2 FTEs. No SCI invoicing appears in FY2022–FY2024, consistent with the concentration of awards in 2025 and 2026. Tempus self-performs all labor on federal service contracts reported under SCI (0% subcontractor hours across prime records), and holds no named subcontractors across the federal prime contract footprint. Work is performed at Tempus facilities in Chicago, Illinois and Fredericksburg, Virginia. The company's category concentration reflects its genomic testing and laboratory-analysis focus: 8 awards under NAICS 621511 (Medical Laboratories), 4 under NAICS 541380 (Testing Laboratories and Services), with the balance split between life-sciences R&D categories. The corresponding PSC codes track that framing — 11 awards under Reference Laboratory Testing, with the remainder distributed across health R&D and scientific data analysis categories.
Quick answers
Is Tempus AI, Inc. registered in SAM.gov?
Yes. Tempus AI, Inc.'s SAM.gov registration is active through August 18, 2027.
What is Tempus AI, Inc.'s CAGE code?
Tempus AI, Inc.'s CAGE code is 7WPH7, and its Unique Entity ID (UEI) is PW4TQZ3KDLU3.
How much has Tempus AI, Inc. received in federal contracts?
Federal contracts obligated $18,460,020 to Tempus AI, Inc. in fiscal year 2025 and $61,050,534 in fiscal years 2023 through 2027.
How does Tempus AI, Inc. rank among federal contractors?
Tempus AI, Inc. ranked #12 in NAICS 621511, #14 in NAICS 6215 and #16 in PSC AN12 in FY2025.
What is Tempus AI, Inc.'s most recent federal award?
Tempus AI, Inc.'s most recent federal contract award is Tasso+ assay testing for MVP program (36C24E26N0239), from Veterans Integrated Service Network 4 (VHA), on September 15, 2026.
On GovTribe
See Tempus AI, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors